CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $210,525 | -2.5% | 3,750 | +13.6% | 0.01% | -22.2% |
| Q3 2022 | $216,000 | +7.5% | 3,300 | 0.0% | 0.01% | +28.6% |
| Q2 2022 | $201,000 | -2.9% | 3,300 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $207,000 | -17.2% | 3,300 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $250,000 | -32.2% | 3,300 | 0.0% | 0.01% | -42.9% |
| Q3 2021 | $369,000 | -30.9% | 3,300 | 0.0% | 0.01% | -30.0% |
| Q2 2021 | $534,000 | +32.8% | 3,300 | 0.0% | 0.02% | +11.1% |
| Q1 2021 | $402,000 | -20.4% | 3,300 | 0.0% | 0.02% | -47.1% |
| Q4 2020 | $505,000 | +83.0% | 3,300 | 0.0% | 0.03% | +54.5% |
| Q3 2020 | $276,000 | +13.6% | 3,300 | 0.0% | 0.02% | -8.3% |
| Q2 2020 | $243,000 | -99.8% | 3,300 | 0.0% | 0.02% | +20.0% |
| Q1 2020 | $139,953,000 | -30.4% | 3,300 | 0.0% | 0.02% | -23.1% |
| Q4 2019 | $200,987,000 | – | 3,300 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |